Price Target Increase#
Evercore ISI has raised its price target for Fortrea shares (NASDAQ:FTRE) from $14 to $20 while keeping an Outperform rating. Currently, the stock is trading at $15.29 and has seen an impressive 107% return over the past year. However, some analysts suggest that the shares might be overvalued at this price.
Factors Supporting Growth#
The firm highlighted several reasons for the optimistic outlook, including improved bookings and stronger engagement with both biotech companies and new clients. Additionally, the rollout of the FIT program and careful management of the company’s finances have contributed to Fortrea's positive trajectory. Notably, Fortrea has reduced about 35% of its original debt and has over $500 million in liquidity, indicating a solid financial position.
Updated Financial Estimates#
Evercore ISI has revised its estimates for Fortrea, setting the new price target at approximately 12 times the expected earnings before interest, taxes, depreciation, and amortization (EBITDA) for fiscal year 2027. The firm noted that Fortrea's training plan is on track, with early signs of improved execution.
Earnings Performance#
In its recent financial report for the first quarter of 2026, Fortrea posted an earnings per share (EPS) of $0.16, significantly surpassing the expected $0.05, resulting in a 220% surprise. However, the company reported a revenue decline, with earnings of $636.5 million, which fell short of the anticipated $864.6 million, marking a 26.39% miss. Despite these challenges, Fortrea's ability to manage costs effectively has helped maintain profitability, drawing attention to its financial performance in a competitive environment.